Mallinckrodt plc, of Dublin, said its subsidiary, Cadence Pharmaceuticals Inc., entered settlement and license agreements with Fresenius Kabi USA LLC, part of Fresenius Kabi AG, of Bad Homburg, Germany, to end the patent litigation regarding Ofirmev (acetaminophen) injection.